soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Effects of on Heart Failure in Diabetes and Chronic Kidney Disease in the FLOW Oral Semaglutide Cuts Cardiovascular Risk

Emerging peptides under study may suppress appetite via brain pathways that avoid the gastric slowing responsible for common GI side effects of current GLP-1 drugs

Licensed 503A compounding pharmacies must meet specific regulatory standards, including quality control, sterile technique certification, and pharmacist verification before dispensing any medication

Jones MD, Santo JGF, Yakub B, Dennison M, Master H et al (2010) The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance

Tirzepatide is a dual GLP-1 and GIP receptor agonist, which is part of why SURMOUNT-1 participants lost more weight on average than STEP 1 participants lost on semaglutide, though the two trials were not run head-to-head in the same population

Patients and providers alike are curious: Is it safe to switch from semaglutide to tirzepatide